User Fee Negotiators Far Apart: Industry Seeks To Delay New Fee Levels Until FDA Improves Performance
This article was originally published in The Gray Sheet
Executive Summary
Device industry reps say industry-paid FDA user fees should be reauthorized for only two years, not five, to allow ongoing changes to FDA's pre-market review programs to sink in before a more meaningful user fee package is passed.